Bicara Therapeutics (BCAX) shares plunged 44% after the company said late Thursday that updated interim data from its Phase 1/1b trial of ficerafusp alfa with pembrolizumab in patients with first-line recurrent/metastatic head and neck squamous cell carcinoma showed a 64% objective response rate, including several complete responses. Median overall survival and duration of response were not yet reached as of the December 2024 data cutoff.
More than 5.19 million shares traded intraday compared with a daily average of about 588,000.
Deckers Outdoor's (DECK) strong fiscal Q4 results were overshadowed by sales growth deceleration at its Hoka sneaker brand and potential demand weakness from price increases, prompting KeyBanc Capital Markets to downgrade the footwear and apparel company's stock.
Shares of Deckers sank 18% following an increase in intraday trading volume to over 13.9 million from a daily average of about 3.2 million.
Ross Stores (ROST) overnight warned that elevated tariffs could pressure profitability, noting that over half its merchandise originates from China despite limited direct imports. Citing ongoing macroeconomic uncertainty and shifting trade policies, the company withdrew its full-year sales and earnings guidance.
Shares declined 10%, with intraday trading volume rising to over 13.1 million versus a daily average of about 3.2 million.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。